Tumour rejection by gene transfer of 4-1BB ligand into a CD80+ murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells

Immunology

Volumn 101, Issue 4, 2000, Pages 541-547

  Mogi, S ^a   Sakurai, J ^a   Kohsaka, T ^a   Enomoto, S ^b   Yagita, H ^c   Okumura, K ^c   Azuma, M ^a,b  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD137 LIGAND; CD86 ANTIGEN; LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE TRANSFER; HOST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR IMMUNOLOGY; TUMOR REJECTION;

EID: 0034536944     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2000.t01-1-00138.x     Document Type: Article

References (35)

1. CD28 interaction with B7 co-stimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes
2. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
3. + T cells by B7-transfected melanoma cells
4. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
5. CD28-B7 interactions in T-cell activation
6. Tumor immunogenicity determinants the effect of B7 costimulation on T cell-mediated tumor immunity
7. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma
8. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells
9. Antittumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules
10. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
11. Molecular cloning of a ligand for the inducible T cell gene 4-1 BB. A member of an emerging family of cytokines with homology to tumor necrosis factor
12. Molecular and biological characterization of human 4-1BB and its ligand
13. cDNA sequences of two inducible T-cell genes
14. Inducible T cell antigen 4-1BB. Analysis of expression and function
15. 4-1BB T cell antigen binds to mature B cells and macrophages, and cotimulates anti-μ-primed splenic B cells
16. Costimulation of CD28- T lymphocytes by 4-1BB ligand
17. CD28-independent, TRAF-dependent costimulation of resting T cells by 4-1BB ligand
18. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
19. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
20. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway
21. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine
22. Effect of PSK, a protein polysaccharide, on pulmonary metastasis of C3H mouse squamous cell carcinoma
23. Tumour destruction and proliferation kinetics following periodic, low power light, haematoporphyrin oligomers mediated photodynamic therapy in the mouse tongue
24. Autocrine growth and tumorgenicity of interleukin 2-dependent helper T cells transfected wih IL-2 gene
25. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells
26. Multicolor immunofluorescence and flow cytometry. Methods: A companion
27. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses
28. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination
29. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BBI in interleukin-2 production and immunotherapy
30. Host B7-1 and B7-2 Costimulatory molecules contribute to the eradication of B7-1 transfected P815 tumor cells via a CDS+ T cell-dependent mechanism
31. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization
32. B7-negative versus B7-positive P815 tumor. Differential requirements for priming of an antitumor immune response in lymph nodes
33. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 cells
34. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
35. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP